(Total Views: 427)
Posted On: 07/30/2019 2:17:20 AM
Post# of 432
See below: It doesn't take more than a little bit of foresight to see that Global Stem Cells will be an acquisition target similar to Oriris Theraputics being taken over by Smith & Nephew for $19.00 cash in April of 2019. Anyone who talks about valuation needs to look at the stem cells market growth and companies already participating in public markets.
17 April 2019
Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces completion of the acquisition of Osiris Therapeutics, Inc. for $19.00 per share in cash, representing a total equity value of approximately $660 million. Osiris is a fast growing company delivering regenerative medicine products including skin, bone graft and articular cartilage substitutes.
The acquisition is expected to accelerate growth from Smith & Nephew’s Advanced Wound Management franchise.
Osiris delivered revenue of $142.8 million for the year ended 31 December 2018, a 20.5% increase over the prior year.
Enquiries
17 April 2019
Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces completion of the acquisition of Osiris Therapeutics, Inc. for $19.00 per share in cash, representing a total equity value of approximately $660 million. Osiris is a fast growing company delivering regenerative medicine products including skin, bone graft and articular cartilage substitutes.
The acquisition is expected to accelerate growth from Smith & Nephew’s Advanced Wound Management franchise.
Osiris delivered revenue of $142.8 million for the year ended 31 December 2018, a 20.5% increase over the prior year.
Enquiries
(0)
(0)
Louis Pasteur -- chance favours only the prepared mind.
Lecture, University of Lille (7 December 1854)
Lecture, University of Lille (7 December 1854)
